This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Source: Motley Fool
2026-03-16 19:33:01 ET
On February 17, 2026, Cormorant Asset Management disclosed in a regulatory filing that it sold its entire stake in Arcellx (NASDAQ:ACLX) , an estimated $63.63 million transaction based on last-disclosed position values.
According to an SEC filing dated February 17, 2026, Cormorant Asset Management sold 775,000 shares of Arcellx, fully liquidating its position. The quarter-end value of the fund’s Arcellx stake declined by $63.63 million as a result of the exit.
Arcellx Inc.
NASDAQ: ACLX
ACLX Trading
0.04% G/L:
$115.08 Last:
1,195,659 Volume:
$115.04 Open:
ACLX Latest News
March 16, 2026 07:33:01 pm
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
ACLX Stock Data
$3,888,009,846
37,694,730
1.62%
80
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
